AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2021
Nov 17, 2021
31289_dirs_2021-11-17_90f3363c-d16a-4004-a2cd-61789830647c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-11-16
Reporting Person: LAMATTINA JOHN L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-16 | Common Stock | M | 4835 | $32.3 | Acquired | 30233 | Direct |
| 2021-11-16 | Common Stock | S | 4835 | $161.8571 | Disposed | 25398 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-11-16 | Non-Qualified Stock Option (right to buy) | $32.3 | M | 4835 | Disposed | 2023-06-11 | Common Stock (4835) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.36 to $164.12, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 11, 2013, and fully vested on the first anniversary of the grant date.